Dalia Barsyte-Lovejoy

Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression.

c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism.

Cloning and characterization of teneurin C-terminus associated peptide (TCAP)-3 from the hypothalamus of an adult rainbow trout (Oncorhynchus mykiss).

Promoter-binding and repression of PDGFRB by c-Myc are separable activities.

Teneurin proteins possess a carboxy terminal sequence with neuromodulatory activity.

Cancer therapeutics: targeting the dark side of Myc.

The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis.

Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells.

Teneurin carboxy (C)-terminal associated peptide-1 inhibits alkalosis-associated necrotic neuronal death by stimulating superoxide dismutase and catalase activity in immortalized mouse hypothalamic cells.

CUL7 is a novel antiapoptotic oncogene.

Evolution of complementary peptide systems: teneurin C-terminal-associated peptides and corticotropin-releasing factor superfamilies.

Characterization of a corticotropin-releasing factor (CRF)/diuretic hormone-like peptide from tunicates: insight into the origins of the vertebrate CRF family.

A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.

Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.

Histone recognition and large-scale structural analysis of the human bromodomain family.

Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5.

Association of UHRF1 with methylated H3K9 directs the maintenance of DNA methylation.

C-terminal processing of the teneurin proteins: independent actions of a teneurin C-terminal associated peptide in hippocampal cells.

Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.

Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain.

Systems approaches to genomic and epigenetic inter-regulation of peptide hormones in stress and reproduction.

An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.

Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.

A chemical tool for in vitro and in vivo precipitation of lysine methyltransferase G9a.

(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.

A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3).

LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.

Discovery of a Dual PRMT5-PRMT7 Inhibitor.

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.

A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.

MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin.

Discovery of a Potent Class I Protein Arginine Methyltransferase Fragment Inhibitor.

Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.

An Integrative Proteomic Approach Identifies Novel Cellular SMYD2 Substrates.

Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening.

Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.

The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity.

The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

Targeting human SET1/MLL family of proteins.

Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors.

Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3).

TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma.

Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities.

LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.

Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression.

Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.

A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.

Teneurin C-Terminal Associated Peptide (TCAP)-1 and Latrophilin Interaction in HEK293 Cells: Evidence for Modulation of Intercellular Adhesion.

Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells.

Targeting protein methylation: from chemical tools to precision medicines.

Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1).

Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.

A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor.

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.

SETD7 at the heart of chromatin factor interplay.

Synthetic Peptides as Therapeutic Agents: Lessons Learned From Evolutionary Ancient Peptides and Their Transit Across Blood-Brain Barriers.

Discovery of a chemical probe for PRDM9.

Telomere dysfunction cooperates with epigenetic alterations to impair murine embryonic stem cell fate commitment.

Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor.

Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response.

Author Correction: Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response.

Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.

PRMT5 inhibition disrupts splicing and stemness in glioblastoma.

A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6.

Protein arginine methylation: from enigmatic functions to therapeutic targeting.

Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders.

Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.

Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid.

Structure and Function of Protein Arginine Methyltransferase PRMT7.

A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.

PRMT5 regulates ATF4 transcript splicing and oxidative stress response.

PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade.

Validating Small Molecule Chemical Probes for Biological Discovery.

PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.

Chemical biology and pharmacology of histone lysine methylation inhibitors.

Enzymatic nucleosome acetylation selectively affects activity of histone methyltransferases in vitro.

Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical Probes.

Distal extracellular teneurin region (teneurin C-terminal associated peptide; TCAP) possesses independent intracellular calcium regulating actions, : A potential antagonist of corticotropin-releasing factor (CRF).

Skeletal muscle metabolism and contraction performance regulation by teneurin C-terminal-associated peptide-1.